ECHODYNE
15.4.2024 09:01:30 CEST | Business Wire | Press release
Echodyne, the radar platform company, is excited to announce it will be addressing the second annual Counter UAS Technology Europe 2024 conference, taking place at the Marriott Hotel Grosvenor Square in London over April 16-17, 2024. Echodyne VP of Marketing, Leo McCloskey, will discuss important counter-UAS developments in accuracy and mobility. Echodyne’s participation in this year’s event comes on the heels of significantly expanding its footprint in the region with new, European-based team members.
The conference is hosted by SAE Media Group and focuses on gathering European C-UAS stakeholders to address the growing proliferation of small drones and unmanned aircraft system (UAS) technology and the need for European armed forces and security agencies to protect critical national infrastructure and personnel at home and abroad by way of cutting-edge, C-UAS operations.
Drones are an increasing threat beyond the battlefield with payload and operational capabilities that challenge existing sensors and systems. From low, slow, and very effective small UAS to larger Group 3 UAS, the threat to logistics, missions, and warfighters is vast and expanding. Part of the challenge is sensors that can accurately track and deliver precise airspace coordinates of the intruding UAS, for which Echodyne’s metamaterials electronically scanned array (MESA®) are uniquely capable.
Cost symmetry is another challenge, with non-state actors spending small amounts on UAS weapons that require multi-million dollar systems to defeat. Echodyne’s radars achieve the optimal balance of low-cost, commercial off-the-shelf (COTS) advanced technology and high-performance, active beamforming ESA precision to create the most powerful, low-SWaP radars on the market. With both processed and unprocessed data integration options, Echodyne radars generate the most accurate data for detecting, tracking, targeting, and mitigating UAS threats.
“Solving the ‘drone problem’ requires technology and software that, when integrated, contributes high-fidelity, actionable data from attritable COTS platforms,” said Todd Fraser, Chief Revenue Officer at Echodyne. “Customer requirements are rapidly and radically changing, from fixed and portable to highly mobile, from crewed to uncrewed to platforms, from range as the sole driver to greater emphasis on spatial accuracy. Echodyne is expanding to meet increasing customer demand across Europe, Middle East, and Africa for low SWaP, commercially-exportable radars with superior ESA performance.”
Those interested in learning more about Echodyne’s radar for C-UAS operations, including remote weapons stations (RWS), short-range air defense (SHORAD) programs, and more are invited to attend Echodyne’s session at the Counter UAS Technology Europe 2024 Conference at 11 am BST on April 16, 2024. Those who are unable to attend can connect directly with a member of the Echodyne team here.
About Echodyne
Echodyne, the radar platform company, is a U.S. designer and manufacturer of advanced radar solutions for defense, government, and commercial market applications. The company’s proprietary metamaterials electronically scanned array (MESA®) architecture is a rare breakthrough in advanced radar engineering. Echodyne’s innovative MESA radars use standard materials and manufacturing processes to shatter unit cost barriers for high performance radar. The result is a solid-state, low-SWaP, exportable, commercial radar with advanced software capabilities that delivers superior performance, unparalleled data integrity, and exceptional situational awareness. Privately held, the company is backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, Northrop Grumman, and Supernal, among others. For more information, please visit: Echodyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415117922/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release
Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
